Shikari® (S-ATB) Anti-Bevacizumab ELISA

Enzyme immunoassay for the qualitative determination of specific antibodies to Bevacizumab (Avastin®)  in serum and plasma.

This kit has been especially developed for the qualitative determination of specific antibodies to Bevacizumab in serum and plasma samples.

The Matriks Biotek Antibody to Bevacizumab (Avastin®)* Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the quantitative determination of antibodies to Bevacizumab (Avastin) in serum and plasma.

As with all therapeutic proteins, there is a potential for immunogenicity. Accoring to the manufacturers product insert; the incidence of antibody development in patients receiving Avastin has not been adequately determined because the assay sensitivity was inadequate to reliably detect lower titers. Enzyme-linked immunosorbent assays (ELISAs) were performed on sera from approximately 500 patients treated with Avastin, primarily in combination with chemotherapy. High titer human anti-Avastin antibodies were not detected. Immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Avastin with the incidence of antibodies to other products may be misleading. The Matriks Biotek Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-Bevacizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures.Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work.